Jasdave S. Chahal, Ph.D., Lead Scientist at Tiba Biotech, holds a B.Sc. with honors in Biopharmaceutical Science from the University of Ottawa, and a Ph.D. in molecular biology from Princeton University. He began his postdoctoral research in 2013 with Dr. Hidde Ploegh at the Whitehead Institute at MIT to focus on vaccinology and immunotherapy, initiating projects to engineer RNA molecules as vectors against infectious disease and cancer. His published work demonstrated the effectiveness of these synthetic RNA payloads delivered with dendritic nanomaterials against viral and complex parasitic diseases in animal models, and extended research to immuno-oncology, epitope-screening, and antigen-identification applications. He transitioned to the MIT’s Koch Institute for Integrative Cancer Research in 2016 to further refine the dendrimer-based delivery technology before co-founding Tiba. Jasdave leads R&D activities at the company, advancing a range of academic, government, and industry collaborations developing novel RNA-based payloads and targeted delivery solutions to address infectious disease, cancer, and inflammatory disorders.